May 7, 2021

 CHAIN has developed a platform technology called CADDTM for oral drug delivery based on living bacteria (known as live biotherapeutics).  CADDTM is unique, transformational with broad clinical applicability. US and EU patents describing the use of CADDTM to treat inflammatory bowel disease have recently been granted. Marlow, UK – 7th May 2021 – FOR IMMEDIATE […]

January 4, 2021

Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Marlow, UK – 4th January 2021 – FOR IMMEDIATE RELEASE CHAIN Biotechnology (CHAIN), a UK-based microbiome therapeutics company, focused on the development of oral vaccines, announced today that Heads of […]

June 22, 2020

Following a 2-month closure, CHAIN reopened its laboratories in Nottingham on the 1st June. This comes after a risk assessment and change to working practices to maintain safe working for staff in the labs and office. MediCity has also implemented new measures in the building to support safe working practices which have also contributed to […]

May 11, 2020

An Oxford based nutritional company, TdeltaS Ltd (TΔS®), has developed and commercialised a proprietary ketone ester, which can be used as a food to improve human physical performance and cognitive function in health and disease.  The Company’s product, ΔG®, is a ketone monoester that is marketed by HVMN Inc. in the USA for use in their sports […]

April 20, 2020

CHAIN is pleased to announce a new 18-month research collaboration with Associate Professor John Heap and his research group at the University of Nottingham.     Dr Heap is Associate Professor of Synthetic Biology in the School of Life Sciences at the University of Nottingham, where he is also part of the newly-formed Biodiscovery Institute […]

April 2, 2020

Andrew has had a distinguished career at Danisco/DuPont, acting as Chief Scientific Officer (2008–2011) for Danisco and Chief Scientist for DuPont Nutrition & Health (2011–2019).  He was appointed a DuPont Fellow in 2016 and played a key role in helping build DuPont’s microbiome platform.      Having retired from DuPont at the end of 2019, […]

November 5, 2019

”An expansive view of design has been adopted at CHAIN Biotechnology, which is developing new therapeutics based on living microbes where the “bug is the drug.” These drugs are based on a single strain of Clostridium bacteria that is naturally found in the gut, but which has been deliberately engineered to carry a therapeutic payload, such as […]

July 22, 2019

CHAIN has worked closely with the University of Nottingham since our beginning, and it is our pleasure to announce Anastasiya Buryak the winner of the CHAIN Biotechnology Award for Best Student Ambassador for Biotech and Best Academic Performance. CHAIN attended the award ceremony last week at the University’s Sutton-Bonnington Campus and we caught up with […]

July 2, 2019

Oxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK grant to CHAIN Biotechnology Ltd (CHAIN) and the University of Oxford to develop live biotherapeutics that support oral delivery for OVM’s recombinant overlapping peptide (ROP) […]

June 19, 2019

CHAIN’s drug delivery platform and lead product, β-hydroxybutyrate, is highlighted in a new report ‘Catalysing Investment and Growth’, released by the BioIndustry Association this week. Our microbiome therapeutics are based on spores of Clostridium bacterial species. We have successfully demonstrated scale-up of bacterial spore production with our partners at Porton Biopharma Ltd as part of the Industrial Strategy […]